Biocom's program serves to extend effective, well-established and easy-to-perform self-collection nasal swab testing to over 1,300 members across the state under the Food and Drug Administration 's Emergency Use Authorization framework.
Test purchases come equipped with Everlywell Lens, a comprehensive reporting dashboard for human resource representatives, which gives organizations visibility into the status of individual kits, from registration to results.
The program with Everlywell will provide Biocom members access to rt-PCR tests that will determine the presence or absence of RNA from the SARS-CoV-2-virus.
Met with the highest standards of quality, safety, and reliability, Everlywell's straightforward sample collection, free shipping, and physician-reviewed results and insights ensure that we are connecting our members with one of the best testing solutions in the market.
The laboratories used by Everlywell are CLIA-certified and many are CAP-accredited, which means they must meet or exceed high precision, accuracy, and validity standards, obtain both state and federal certifications, and submit themselves to regular inspections as well as independent third-party performance verifications.
Biocom works on behalf of over 1,300 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge workforce development and STEM education programs, and create robust value-driven purchasing programs.
Biocom a public voice for research institutions and life science companies that fuel the California economy.
Biocom Purchasing Group offers member-driven strategic sourcing solutions. Biocom members save on average 15-25x their membership dues through the Biocom Purchasing Group.
In 2019, members collectively saved USD 280m and brought more ideas to market through a broad range of products, services and technologies offered by endorsed Purchasing Group suppliers.
Everlywell connects individuals to certified labs offering a suite of validated lab tests including Cholesterol, Heart Health, Fertility, STIs, Lyme Disease, Testosterone, Thyroid and more, including one of the only FDA-authorized at-home sample collection test kits for COVID-19 and the first at-home sample collection test kits for fertility, high-risk HPV, and indoor and outdoor allergies.
Prices start at USD 49 and tests are generally covered by Flexible Spending and Health Savings Accounts.
The Austin-based company was founded in 2015 and is advised by a Scientific advisory board that includes some of the nation's top scientists from Harvard, MIT, Google and NYU. Everlywell was selected as one of Fast company's Most Innovative Companies in 2019.
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
FDA accepts Xspray Pharma's NDA for XS003 with PDUFA date set for June 2026
Citius Oncology and McKesson sign US distribution agreement for LYMPHIR
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Antengene reveals ATG-022 clinical data at ESMO 2025
WeightWatchers launches RxFlexFund to expand affordable GLP-1 access for employers and employees
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study